对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英

上传人:飞*** 文档编号:57049768 上传时间:2018-10-18 格式:PPT 页数:37 大小:1.29MB
返回 下载 相关 举报
对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英_第1页
第1页 / 共37页
对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英_第2页
第2页 / 共37页
对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英_第3页
第3页 / 共37页
对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英_第4页
第4页 / 共37页
对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英_第5页
第5页 / 共37页
点击查看更多>>
资源描述

《对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英》由会员分享,可在线阅读,更多相关《对多支血管的冠心病选择经皮血管成形术或者外科手术的血管成形术_Verghes英(37页珍藏版)》请在金锄头文库上搜索。

1、Percutaneous or Surgical Revascularization for Multivessel Coronary Artery Disease?,Verghese Mathew, MD, FACC Consultant, Division of Cardiovascular Diseases and Department of Radiology Professor of Medicine, Mayo Clinic College of Medicine,Revascularization Strategies,How do we decide?,Anatomy Clin

2、ical Patientpresentation preference,Risk vs. Benefit,Invasive Therapies,Low Risk Patient,High Risk Patient,Some acute risk,Less long-term risk reduction,Greater acute risk,Greater long-term risk reduction,12-Year Survival in Patients with CAD,50 35-49 35,Emond M et al: Circ 90:2645, 1994,23,467 Medi

3、cally-Treated Patients in CASS Registry,LVEF,CP1203018-2,12-Year Survival in Patients with CAD,No CAD 1 vessel 2 vessel 3 vessel,Emond M et al: Circ 90:2645, 1994,23,467 Medically-Treated Patients in CASS Registry,CP1203018-1,Clinical Presentation,Age Acute ischemic syndrome versus chronic stable an

4、gina Prior cardiac history (MI, CABG, intervention) Co-morbid conditions (diabetes, cerebrovascular disease, renal disease, lung disease) Functional impairment Ischemic burden,Extension of Survival with CABG vs Medical Therapy After 10 Years,CP1203018-14,Extension of survival (mo),Yusuf S et al: Lan

5、cet 344:563, 1994,Overall,Vessel disease 1/2 vessels 3 vessels Left main,LV function Normal Abnormal,Exercise test Normal Abnormal,Angina Class 0, I, II Class III, IV,Low Moderate High,Low Moderate High,VA risk score,Stepwise risk score,CABG vs Stenting for MVD Meta-Analysis of ARTS, ERACI-II, MASS-

6、II and SOS,Circ 118, 2008,Days,Event-Free Survival Analysis of Death,1,518 1,472 1,456 1,440 1,406 1,3471,533 1,479 1,457 1,439 1,412 1,349,Overall survival (%),P=0.78,Days,Repeat Revascularization,1,518 1,204 772 740 707 6651,533 1,428 927 911 882 855,P0.0001,Overall survival (%),Days,Death, Stroke

7、 or MI,1,518 1,381 913 896 872 8461,533 1,377 908 891 868 845,Overall survival (%),P=0.64,Days,Major Adverse Cardiac and Cerebrovascular Events,1,518 1,153 729 691 657 6161,533 1,332 867 846 812 785,P2xConcomitant cardiac surgery,SYNTAX Inclusion Criteria,3-vessel disease and/or left main disease To

8、tal occlusion without time limitation Previous stroke 1 month Renal and respiratory insufficiency Decreased pump function Myocardial ischemia (unstable-silent-stable) Patients with comorbidity,Real world patient population,PCI n=198,TAXUS* n=903,CABG n=897,vs,CABG n=1077,no f/u n=428,5yr f/u n=649,T

9、wo Registry Arms N=1275,Randomized Arms N=1800,Heart Team (surgeon & interventionalist),Amenable for only one treatment approach,Amenable for both treatment options,Stratification: LM and Diabetes,LM 33.7%,3VD 66.3%,LM 34.6%,3VD 65.4%,23 US Sites,62 EU Sites,+,SYNTAX Trial Design,*TAXUS Express,Cumu

10、lative rate (%),SYNTAX: Outcomes,NEJM 360(10), 2009,Cumulative rate (%),Death from Any Cause,Death from Any Cause, Stroke, or MI,Repeat Revascularization,Major Adverse Cardiac or Cerebrovascular Event,Months since randomization,Cumulative rate (%),Cumulative rate (%),Months since randomization,P=0.3

11、7,P=0.99,3.5,P0.001,P=0.002,Months since randomization,Months since randomization,PCI,CABG,4.4,PCI,7.7,7.6,CABG,PCI,CABG,13.5,5.9,17.8,12.4,PCI,CABG,SYNTAX CABG/PCI Registries,SYNTAX appendix: NEJM, 2009,Reasons for CABG,Complex anatomy 70.9% Untreatable chronic 22.0% total occlusion Unable to take

12、0.9% anti-platelet medications Patient refused PCI 0.5% Other 5.7%,Reasons for PCI,Comorbidity 70.7% No graft material 9.1% Patient refused CABG 5.6% Small or poor quality 1.5% of distal vessel Other 13.1%,n=644,n=192,SYNTAX Score,Number & location of lesions,Tortuosity,Thrombus,Bifurcation,Total Occlusion,Diffuse,Left Main,Dominance,SYNTAX Score,

展开阅读全文
相关资源
相关搜索

当前位置:首页 > 行业资料 > 其它行业文档

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号